Your browser doesn't support javascript.
loading
Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.
Coart, Elisabeth; Suciu, Stefan; Squifflet, Pierre; Saad, Everardo D; Moshyk, Andriy; de Schaetzen, Gaetan; Buyse, Marc; Weber, Jeffrey S; Eggermont, Alexander; Kotapati, Srividya.
Afiliación
  • Coart E; International Drug Development Institute (IDDI), Avenue Provinciale, 30, 1340, Louvain-la-Neuve, Belgium. Electronic address: elisabeth.coart@iddi.com.
  • Suciu S; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Squifflet P; International Drug Development Institute (IDDI), Avenue Provinciale, 30, 1340, Louvain-la-Neuve, Belgium.
  • Saad ED; International Drug Development Institute (IDDI), Avenue Provinciale, 30, 1340, Louvain-la-Neuve, Belgium.
  • Moshyk A; Health Economics and Outcomes Research, Bristol Myers Squibb, 100 Nassau Park Blvd, Princeton, NJ, 08540, USA.
  • de Schaetzen G; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Buyse M; International Drug Development Institute (IDDI), Avenue Provinciale, 30, 1340, Louvain-la-Neuve, Belgium.
  • Weber JS; Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, 522 First Avenue, New York, NY, 10016, USA.
  • Eggermont A; Princess Maxima Center, Utrecht, the Netherlands.
  • Kotapati S; Health Economics and Outcomes Research, Bristol Myers Squibb, 100 Nassau Park Blvd, Princeton, NJ, 08540, USA.
Eur J Cancer ; 137: 171-174, 2020 09.
Article en En | MEDLINE | ID: mdl-32777716
INTRODUCTION: Recent changes in the adjuvant treatment of melanoma have raised interest in confirming relapse-free survival (RFS) as a surrogate for overall survival (OS). METHODS: We explore this issue with the meta-analytic framework, using individual patient data from the European Organisation for Research and Treatment of Cancer (EORTC) 18071 trial of ipilimumab and published results from other adjuvant trials. RESULTS: The individual patient data analysis results at a median follow-up of 5.3 years showed a strong association between RFS and OS at the patient level (ρ = 0.84; 95% confidence interval [CI]: 0.82-0.87) and a moderate association at the trial level (R2 = 0.59; 95% CI: 0.08-1.00). CONCLUSIONS: The trial-level association previously observed in interferon-based trials appeared to be maintained when the EORTC 18071 results were added to a regression analysis using published results from other trials. More data from adjuvant trials are required to confirm the strength of association between RFS and OS in this setting.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Quimioterapia Adyuvante / Inhibidores de Puntos de Control Inmunológico / Melanoma Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Quimioterapia Adyuvante / Inhibidores de Puntos de Control Inmunológico / Melanoma Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido